Insider Selling: TG Therapeutics Inc (TGTX) CFO Sells $272,051.00 in Stock
TG Therapeutics Inc (NASDAQ:TGTX) CFO Sean A. Power sold 32,006 shares of TG Therapeutics stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $8.50, for a total value of $272,051.00. Following the completion of the transaction, the chief financial officer now directly owns 517,464 shares of the company’s stock, valued at $4,398,444. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Shares of TG Therapeutics Inc (NASDAQ:TGTX) opened at $9.10 on Friday. TG Therapeutics Inc has a 12-month low of $4.10 and a 12-month high of $15.35. The company has a market capitalization of $642.94, a PE ratio of -4.72 and a beta of 1.30.
TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.05). TG Therapeutics had a negative net margin of 73,217.77% and a negative return on equity of 151.21%. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. equities analysts predict that TG Therapeutics Inc will post -1.87 EPS for the current year.
A number of institutional investors have recently modified their holdings of TGTX. State Street Corp increased its position in TG Therapeutics by 274.4% in the 2nd quarter. State Street Corp now owns 2,638,683 shares of the biopharmaceutical company’s stock valued at $26,515,000 after buying an additional 1,933,896 shares in the last quarter. Artal Group S.A. bought a new stake in TG Therapeutics in the 2nd quarter valued at about $5,025,000. Franklin Resources Inc. increased its position in TG Therapeutics by 20.6% in the 2nd quarter. Franklin Resources Inc. now owns 2,339,166 shares of the biopharmaceutical company’s stock valued at $23,509,000 after buying an additional 398,916 shares in the last quarter. Kennedy Capital Management Inc. increased its position in TG Therapeutics by 151.6% in the 2nd quarter. Kennedy Capital Management Inc. now owns 565,178 shares of the biopharmaceutical company’s stock valued at $5,680,000 after buying an additional 340,545 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in TG Therapeutics by 14.3% in the 2nd quarter. Vanguard Group Inc. now owns 2,046,427 shares of the biopharmaceutical company’s stock valued at $20,566,000 after buying an additional 255,844 shares in the last quarter. 50.41% of the stock is owned by institutional investors and hedge funds.
Several research analysts have recently weighed in on TGTX shares. ValuEngine lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. HC Wainwright reissued a “buy” rating and issued a $33.00 price objective (up from $18.00) on shares of TG Therapeutics in a research report on Tuesday, November 14th. SunTrust Banks reissued a “buy” rating and issued a $28.00 price objective on shares of TG Therapeutics in a research report on Tuesday, October 3rd. B. Riley reissued a “buy” rating and issued a $21.50 price objective on shares of TG Therapeutics in a research report on Monday, December 11th. Finally, Raymond James Financial reissued a “buy” rating on shares of TG Therapeutics in a research report on Tuesday, December 12th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $25.50.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.